EXEL - Exelixis, Inc.
15.66 +0.21 (1.37%)
After hours: 4:11PM EDT
| Previous Close | 16.27 |
| Open | 16.44 |
| Bid | 15.45 x 4000 |
| Ask | 15.65 x 1200 |
| Day's Range | 15.43 - 16.62 |
| 52 Week Range | 15.43 - 32.20 |
| Volume | 2,710,999 |
| Avg. Volume | 3,394,270 |
| Market Cap | 4.605B |
| Beta (3Y Monthly) | 2.28 |
| PE Ratio (TTM) | 14.99 |
| EPS (TTM) | 1.03 |
| Earnings Date | Nov 1, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.22 |
- Business Wire•14 hours ago
Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
– Combination of cabozantinib and atezolizumab is well tolerated and shows promising anti-tumor activity –
- Business Wire•2 days ago
Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
– Cabozantinib was associated with improved overall survival and progression-free survival irrespective of PD-L1 expression in CABOSUN and METEOR trials –
- Motley Fool•4 days ago
Why Merck's Latest Success Means Trouble for Exelixis Inc.
Selling Cabometyx to an important group of patients is about to get even more difficult.
- Business Wire•4 days ago
Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
Exelixis, Inc. (EXEL) announced today that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
- InvestorPlace•5 days ago
5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage
For whatever the reason — the trade war, Federal Reserve or general market malaise — investors have turned on a variety high-momentum shares. The rout in biotech stocks has been pretty severe. The iShares NASDAQ Biotechnology Index (NYSEARCA:IBB) — the broad sector benchmark — is down roughly 5% in October.
- GlobeNewswire•5 days ago
Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•7 days agoSee what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXEL
- American City Business Journals•11 days ago
Tech and biotech on collision course, squeezed by the Peninsula's limited space
The rapidly growing sectors have been gobbling up workers and office space in San Mateo County. Now they are running into each other's growth ambitions
- Business Wire•14 days ago
Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
– Presentations to include results from the dose escalation stage of phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in previously untreated advanced ren
Market Realist•14 days agoAnalysts Are Mostly Positive on Portola Pharmaceuticals
Portola Pharmaceuticals (PTLA) is focused on the development and commercialization of novel therapies with a special focus on thrombosis and hematologic diseases. Portola Pharmaceuticals currently has two FDA-approved drugs, Andexxa and Bevyxxa. Portola Pharmaceuticals is advancing its investigational drug, cerdulatinib, which is a Syk/JAK inhibitor.
- Zacks•14 days ago
Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Markit•15 days agoSee what the IHS Markit Score report has to say about Exelixis Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Business Wire•15 days ago
Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
– Thyroid cancer is the most rapidly increasing cancer in the U.S., with incidence tripling over the past 30 years –
- TheStreet.com•15 days ago
3 Small Biotech Stocks to Watch in the Fourth Quarter
The S&P 500 had a good summer. The widely followed index rose more than 7% in the third quarter. It was the best quarterly performance for the S&P 500 since 2013. Profits among S&P 500 companies grew some 25% year over year in the first half of 2018 bolstered by robust domestic economic activity and a big drop in the corporate income tax rate.
- ACCESSWIRE•17 days ago
Liver Cancers Rising - Stocks to Watch
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / Liver cancer incidence has more than tripled since 1980. Liver cancer death rates have increased by almost 3% per year since 2000. More than 700,000 people ...
- Investopedia•19 days ago
Top 5 Biotech Stocks for 2018
Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Given Celgene's solid long-term track record, the lackluster year-to-date performance may represent a buying opportunity.
- Simply Wall St.•19 days ago
How Did Exelixis Inc’s (NASDAQ:EXEL) 42% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
- Motley Fool•20 days ago
3 Top Mid-Cap Stocks to Buy in October
These high-growth mid-cap stocks are just what the doctor ordered.
- Business Wire•27 days ago
Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018
— Presentation to be webcast on www.exelixis.com —
- Zacks•28 days ago
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.
- Motley Fool•last month
3 Top Biotech Stocks to Buy Right Now
These biotech stocks are profitable and poised to deliver nice gains for patient investors.
- Benzinga•last month
The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...
- Business Wire•last month
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
– In the phase 3 pivotal CELESTIAL trial, CABOMETYX demonstrated a statistically significant and clinically meaningful overall survival benefit –
- Zacks•last month
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada
Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.
Markit•last monthSee what the IHS Markit Score report has to say about Exelixis Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
